Monte Rosa Therapeutics (GLUE) Other Non-Current Assets (2020 - 2026)

Monte Rosa Therapeutics' Other Non-Current Assets history runs 7 years deep, the most recent figure standing at $4.9 million for Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 1.37% year-over-year to $4.9 million in Q1 2026; TTM through Mar 2026 was $4.9 million, a 1.37% increase from a year earlier, with the FY2025 full-year figure at $148000.0, down 96.96% from the prior year.
• Other Non-Current Assets advanced to $4.9 million in Q1 2026 per GLUE's latest filing, from $148000.0 in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $5.3 million in Q1 2022 and bottomed at $148000.0 in Q4 2025.
• The 5-year median for Other Non-Current Assets is $4.9 million (2024), against an average of $4.1 million.
• Across the five-year window, Other Non-Current Assets jumped 1281.53% in 2024 and sank 96.96% in 2025, its largest moves.
• Year by year, Other Non-Current Assets stood at $4.3 million in 2022, then slumped by 91.85% to $352000.0 in 2023, then soared by 1281.53% to $4.9 million in 2024, then sank by 96.96% to $148000.0 in 2025, then soared by 3242.57% to $4.9 million in 2026.
• Per Business Quant, the three latest GLUE Other Non-Current Assets figures stand at $4.9 million (Q1 2026), $148000.0 (Q4 2025), and $411000.0 (Q3 2025).